We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA granted clearance for a standalone reader to be ...

Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Through the reader, diabetes ...

As it embarks on a widespread effort to remind users of the proper care and keeping of the hand-held readers used with its FreeStyle Libre continuous glucose monitors, Abbott is further expanding the ...

The FreeStyle Libre 3 system is the latest generation in Abbott's FreeStyle Libre portfolio – the most prescribed and affordable integrated continuous glucose monitoring (iCGM) system in the United ...

Abbott announced that the US Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system, which features the world's ...

Abbott (NYSE:ABT) announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using ...

Using near-field communication (NFC) technology, the app transfers glucose data from the sensor to the mobile device, allowing users to track their eight-hour glucose history and real-time patterns ...

- People with diabetes who use the FreeStyle Libre mobile app experience clinically significant improved time in target range - Data reinforce the benefits of mobile apps, which can remotely connect ...

MISSISSAUGA, Ontario, Oct. 4, 2018 /CNW/ -- Abbott (NYSE: ABT) announced today the company has received the Health Canada license of its FreeStyle LibreLink mobile app for use with compatible iOS ...

The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...